Answers are grounded in this paper and cite their sources.
INTRODUCTION. High level expression in tumor cells of various cellular growth factors, their receptors and activation of intracellular signaling pathways take an important part in recurrence of intracranial meningiomas (Grade III). There is a group of patients with aggressive meningiomas characterized by frequent recurrences and low survival rate. The following surgery is associated with high risk of appearance or worsening of neurological deficit, radical tumor removal is not always possible. Radiotherapy is also limited in some cases or not effective enough.AIM. To evaluate the degree of development of the theme of chemotherapy use in patients with meningiomas of different anaplasia degree according to the world literature data; to present our own data on chemotherapeutic treatment of a patient with recurrent meningioma.MATERIALS AND METHODS. The search of printed works in Pubmed, EMBASE, Cohrane Library and eLibrary databases was carried out on the issue of chemotherapeutic treatment use in patients with intracranial meningiomas. There is a description of a clinical case of chemotherapy use in complex treatment of a patient with recurrent intracranial anaplastic meningioma in Polenov Neurosurgical Institute — the branch of Almazov National Medical Research Centre.RESULTS. The results of some experimental studies and clinical use of chemotherapeutic drugs of different groups in patients with intracranial meningiomas are presented. Our own data on chemotherapy use in a patient with recurrent meningioma are given.CONCLUSION. Specific antitumor treatment is a part of complex treatment for patients with recurrent meningiomas Grade II–III. The efficiency and safety of this therapy have been proved in some studies and also shown in our clinical example.
No takes yet. Share an insight, caveat, or question.
Kukanov et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: